Differentiating NSCLC patients from healthy controls, the panel formed by the combination of GAS5 and SOX2OT has higher specificity (81.4%) and sensitivity (83.8%) than either one alone. This evidence concerns the gene SOX2-OT and non-small cell lung carcinoma.